Axcan Helicide “not approvable”
Executive Summary
Axcan's Helicobacter pylori treatment Helicide (subcitrate/metronidazole/tetracycline) is deemed "not approvable" by FDA, company says Aug. 13. FDA's decision is based on a change in manufacturing sites by one of its European raw material suppliers for the drug, Axcan says; FDA will inspect the new facility after Axcan submits its response to FDA, expected by Oct. 30. The company still plans to launch the product by early 2004...
You may also be interested in...
Axcan Helicide “not approvable”
FDA deems Axcan's H. pylori treatment Helicide (bismuth/metronidazole/tetracycline) "not approvable" due to its manufacturer's inability to implement corrective actions with regard to production of bismuth, company says Oct. 6. Axcan had previously received a "not approvable" letter because of manufacturing (1"The Pink Sheet" Aug. 19, 2002, In Brief). Axcan will meet with FDA in the coming weeks to discuss plans to switch manufacturers...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.